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The purpose of this study was to clarify the additive efficacy of short-acting b2-agonists (SABA)
or muscarinic antagonists (SAMA) on dynamic hyperinflation and exercise tolerance in patients
with chronic obstructive pulmonary disease (COPD) who had been treated with long-acting
bronchodilators.
Thirty-two patients with stable COPD who had been treated with long-acting bronchodila-
tors, including long-acting muscarinic antagonists (LAMA), were examined by pulmonary func-
tion tests, dynamic hyperinflation evaluated by the method of step-wise metronome-paced
incremental hyperventilation, and the incremental shuttle walking test before and after inha-
lation of SABA or SAMA. The additive efficacy of the two drugs was analyzed.
Inhalation of SABA and SAMA improved airflow limitation and dynamic hyperinflation in
stable COPD patients who had been treated with LAMA. Inhalation of SABA decreased respira-
tory resistance and the difference in respiratory resistance at 5 Hz and 20 Hz. On the whole,
the additive efficacy of SABA on airflow limitation and dynamic hyperinflation was superior to
that of SAMA. Furthermore, inhalation of SABA resulted in relief of breathlessness during exer-
cise and significant improvement in exercise capacity.63 37 2393; fax: þ81 263 37 2370.
.ac.jp (K. Fujimoto).
2 Elsevier Ltd. All rights reserved.
12.11.013
Additive efficacy of short-acting bronchodilators in COPD 395Inhalation of SABA resulted in significant improvement in exercise tolerance, which may
have been due to improvement in dynamic hyperinflation. Single use of SABA before exercise,
in addition to regular treatment with LAMA, may therefore be useful in stable COPD patients.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Dynamic hyperinflation is attributed to air trapping during
exercise, caused by a decrease in elastic recoil pressure
due to destruction of the alveoli and narrowing of the small
airways in patients with chronic obstructive pulmonary
disease (COPD).1,2 There is a significant relationship
between dynamic hyperinflation and exertional dyspnea or
decreased exercise tolerance in COPD patients,1,3,4 thus
suggesting that dynamic hyperinflation importantly
contributes to exertional dyspnea and impairment of
exercise tolerance in COPD.
According to the GOLD (Global Initiative for Chronic
Obstructive Lung Disease) guidelines,5 bronchodilator
medications play a central role in the management of
stable COPD. The types of bronchodilators most commonly
used are b2-agonists and anticholinergic agents. Of all the
bronchodilators, the long-acting muscarinic antagonists
(LAMA) are the most effective agents for COPD when used
alone. However, COPD patients still have exertional dysp-
nea in their daily lives despite treatment with long-acting
bronchodilators. Short-acting b2-agonists (SABA) and
muscarinic antagonists (SAMA) are recommended to use for
relief of dyspnea as-needed in combination with regular use
of long-acting bronchodilators.5
We have developed the method to evaluate dynamic
hyperinflation by the metronome-paced incremental
hyperventilation (MPIH) technique, and demonstrated that
both SABA and SAMA are effective for reducing dynamic
hyperinflation in COPD.6 We also demonstrated that the
treatment with tiotropium (LAMA) for eight weeks partially
reduced dynamic hyperinflation following the incremental
hyperventilation and improved exercise capacity and
health-related quality of life in COPD.7
We hypothesized that the efficacy of SABA or SAMA on
improving exercise capacity may be due to the relief of
dynamic hyperinflation in stable COPD patients, and that it
may also be additive to the efficacy of regular treatment
with long-acting bronchodilators, including LAMA.Methods
Subjects
Thirty-two stable COPD patients, with FEV1/FVC <70% and
FEV1 values less than 80% of the predicted value after
inhalation of a b2-agonist (moderate-to-very severe COPD),
were recruited from the outpatient clinic of Shinshu
University Hospital from February 2007 to July 2009. COPD
was diagnosed based on clinical history and symptoms, and
pulmonary function characterized by irreversible airflow
limitation in accordance with the GOLD guidelines.5 Allsubjects had smoking-related COPD without a1-antitrypsin
deficiency, and had a smoking history of more than 30
pack-years. Patients with any history of asthma or asth-
matic symptoms as well as patients who had walking
disability, severe arrhythmia or heart failure, or had
suffered from respiratory tract infection or exacerbation of
COPD during the preceding three months were excluded
from the study. All subjects had been treated with tio-
tropium (18 mg, LAMA) once daily for more than three
months, while continuing their other current therapy
without any changes in dose. The subjects were random-
ized into two groups: (1) SABA group (n Z 16) or (2) SAMA
group (nZ 16) as stated in the study protocol. The severity
of COPD, assessed according to the GOLD guidelines, was
stage 2 (n Z 7), stage 3 (n Z 6) and stage 4 (n Z 3) in the
SABA group, and was stage 2 (n Z 3), stage 3 (n Z 11) and
stage 4 (nZ 2) in the SAMA group. There were no significant
differences in the severity of COPD between the two
groups. As the other current therapies being used in addi-
tion to tiotropium, 8 patients were being treated with long-
acting b2-agonists (LABA), 6 with inhaled corticosteroid
(ICS) and 5 with oral theophylline in the SABA group, and 9
patients were being treated with LABA, 7 with ICS and 8
with oral theophylline in the SAMA group. The study was
approved by the institutional research ethics committee of
Shinshu University School of Medicine, and all patients gave
written informed consent to participate.
Protocol
All patients received treatment with tiotropium in the
morning on the day that the pulmonary function tests were
performed, but did not use SABA or SAMA. Pulmonary
function tests including respiratory impedance evaluated
using an impulse oscillation system (IOS), dynamic hyper-
inflation following MPIH, and exercise capacity evaluated
by the incremental shuttle walking test were performed.
After completion of the baseline measurements, the
subjects were then enrolled in a randomized, open-label,
comparative trial to evaluate the additive efficacy of SABA
and SAMA. One group inhaled 20 mg of procaterol hydro-
chloride (SABA; Meptin; Otsuka Pharmaceutical, Tokush-
ima, Japan), while the other group inhaled 0.2 mg of
oxitropium bromide (SAMA; Tersigan; Boehringer Ingel-
heim, Ingelheim, Germany), using a metered-dose inhaler
with a spacer device. Measurements were again performed
30 min after inhalation of procaterol hydrochloride or
60 min after inhalation of oxitropium bromide.
Pulmonary function tests
Spirometry and DLCO were measured using the Chestac-
8800 (Chest Co Ltd, Tokyo, Japan). Functional residual
Table 1 Baseline characteristics of the SABA and SAMA
groups.
SABA (n Z 16) SAMA (n Z 16)
Gender, male/female 15/1 16/0
Age, yr 73  2 76  2
Body mass index, kg/m2 22.1  0.7 20.6  0.6
VC, % of pred. 88.2  5.4 78.2  3.9
IC, L 1.89  0.12 1.71  0.12
FEV1, L 1.16  0.09 1.12  0.11
FEV1, % of pred. 46.1  3.9 42.7  3.6
FEV1/FVC, % 47.2  2.8 44.5  2.4
RV, % of pred. 211.0  17.0 201.8  11.6
TLC, % of pred. 124.1  5.5 120.5  4.0
RV/TLC, % 55.3  2.3 55.8  2.4
DLCO, % of pred. 56.0  5.1 42.6  5.0
Values are means  standard error of the mean.
SABA, short-acting b2 agonist; SAMA, short-acting muscarinic
antagonist; VC, vital capacity; IC, inspiratory capacity; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; RV,
residual volume; TLC, total lung capacity; DLCO, diffusing
capacity for carbon monoxide; pred., predicted.
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Arbor, MI), after which the subject immediately inspired to
total lung capacity and expired maximally to residual
volume, allowing calculation of lung volume and residual
volume/total lung capacity. Local Japanese reference
data,8 developed by the Japanese Respiratory Society,
were used to derive predicted values for FEV1 and vital
capacity, and predicted values for DLCO and lung volumes
(functional residual capacity, residual volume, and total
lung capacity) measured by body plethysmography were
determined using the formulas described by Nishida et al.9
and Boren et al.,10 respectively.
Respiratory impedance was measured using an IOS
(Masterscreen IOS; Erich Jaeger, Hoechberg, Germany), as
described previously.11,12 Respiratory impedance (Zrs) is
characterized by two components: respiratory resistance
(Rrs) and reactance (Xrs). Xrs undergoes a transition from
negative to positive values as frequency (f ) increases. The
resonant frequency (fres) was determined as the frequency
at which Xrs crossed zero and the elastic and inertial forces
were equal in magnitude and opposite. Rrs and Xrs at lower
oscillation frequencies and Rrs at higher frequencies were
evaluated at oscillation frequencies of 5 Hz (Rrs5 and Xrs5)
and 20 Hz (Rrs20). We also measured mean values of Rrs5
and Xrs5 in separated inspiration and expiration of tidal
breath, and evaluated the difference between mean expi-
ratory and inspiratory resistance (DRrs5) and reactance
(DXrs5).
Evaluation of dynamic hyperinflation following
MPIH
Dynamic hyperinflation was evaluated by metronome-
paced hyperventilation, incrementally increasing the
respiratory rate to 20, 30 and 40 breaths/min according to
our previous reports.6,7 End-expiratory lung volume (EELV)
by body plethysmography, inspiratory capacity (IC), and VC
were measured immediately after breathing at resting
respiratory rate for 30 s. Consequently, respiratory rate was
increased to 20, 30 and 40 breaths/min in 30-s increments,
and EELV, IC and VC were again measured immediately
after metronome-paced hyperventilation for 30 s at each
respiratory rate. Inspiratory capacity at resting respiratory
rate was expressed as ICat rest. Inspiratory capacity at rates
of 20, 30, and 40 breaths per minute were expressed as
IC20, IC30, and IC40, respectively. Dynamic hyperinflation
was evaluated by the decreases in inspiratory capacity from
ICat rest to IC20 (ICrest-20; IC20eICat rest), from ICat rest to IC30
(ICrest-30; IC30eICat rest) and from ICat rest to IC40 (ICrest-40;
IC40eICat rest).
Incremental shuttle walking test
The incremental shuttle walking test (ISWT) was conducted
using the protocol described by Singh et al.13 Briefly,
patients were required to walk around a 10-m course with
the walking speed of each 10-m shuttle dictated by an
audio signal played on a compact disk. The test commenced
at an initial speed of 0.5 m per second, with 1-min incre-
ments of 0.17 m per second. The test was terminated when
the patients were too breathless to continue or failed tomaintain the required speed on two consecutive shuttles.
At the end of the test, patients rated their intensity of
breathlessness by using a Borg 0e10 scale.14 Oxygen satu-
ration (PULSOX M2, Minolta Co. Ltd, Japan), heart rate, and
blood pressure were measured prior to and at the termi-
nation of the test.
Data analysis
The values shown in the text, figures and tables represent
means  standard error of the mean (SEM). The data
distribution of the variables in the two groups was first
assessed with Bartlett’s test. Data for the variables that
showed a normal distribution were compared using the
parametric Student’s t-test. Data for the variables that did
not show a normal distribution were compared using the
nonparametric ManneWhitney’s U-test. The data distribu-
tion of the variables at baseline and after the inhalation of
SABA or SAMA was first assessed with Bartlett’s test. Data
for the variables that showed a normal distribution were
compared using the parametric paired t-test. Data for the
variables that did not show a normal distribution were
compared using the nonparametric Wilcoxon signed-rank
test. Simple correlations between variables were exam-
ined by calculating Pearson’s product correlation coeffi-
cient. All statistical analyses were performed using
a Windows-compatible software (Stat Flex version 5.0;
Artech, Osaka, Japan). A value of P < 0.05 was considered
to be significant for the results of all statistical analyses.
Results
Clinical characteristics and pulmonary function
tests
The characteristics and pulmonary function at baseline in
the two groups are shown in Table 1. There were no
Table 2 Effects of SABA or SAMA on FEV1 and respiratory impedance.
SABA (n Z 16) SAMA (n Z 16)
Pre Post Pre Post
FEV1, L 1.16  0.09 1.30  0.09** 1.11  0.11 1.19  0.11**
Rrs5, kPa$s/L 0.47  0.04 0.40  0.04** 0.43  0.03 0.42  0.06
Rrs5-Rrs20, kPa$s/L 0.17  0.02 0.13  0.02* 0.15  0.02 0.13  0.02
Xrs5, kPa$s/L 0.27  0.04 0.21  0.04 0.25  0.03 0.22  0.03
DRrs5, kPa$s/L 0.17  0.04 0.14  0.03 0.14  0.02 0.11  0.02
DXrs5, kPa$s/L 0.16  0.06 0.09  0.05 0.13  0.05 0.09  0.04
fres, Hz 27.0  1.7 23.9  1.5* 26.2  1.1 24.7  1.2
Values are means  standard error of the mean. *p < 0.05 and **p < 0.01 vs. pre inhalation.
SABA, short-acting b2 agonist; SABA, short-acting muscarinic antagonist; FEV1, forced expiratory volume in 1 s; Rrs5 and Rrs20, respi-
ratory resistances at 5 Hz and 20 Hz frequencies; Xrs5, respiratory reactance at 5 Hz frequencies; DRrs5, within-breath changes in Rrs5;
DXrs5, within-breath changes in Xrs5; fres, resonant frequency.
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between the two groups. There were no significant differ-
ences in VC, IC, FEV1, FEV1/FVC, RV, TLC, RV/TLC and DLCO
between the two groups. FEV1 was significantly increased
compared to the baseline in both groups (Table 2).
However, there was a significant difference between the
increase in FEV1 in the SABA group and that in the SAMA
group (0.14  0.02 L vs. 0.08  0.02 L, p < 0.05). Rrs5,
Rrs5eRrs20 and fres were significantly decreased in the
SABA group (Table 2). In contrast, there were no significant
changes following inhalation of SAMA in these parameters
of respiratory impedance.
Dynamic hyperinflation following MPIH
Inspiratory capacity was incrementally decreased as respi-
ratory rate was incrementally increased in all patientsFigure 1 Effects of SABA or SAMA on dynamic hyperinflation
following metronome-paced incremental hyperventilation.
Inspiratory capacity at resting respiratory rate, and the rate of
20, 30 and 40 breath per minute before and after inhalation of
SABA or SAMA are shown. Values are means  standard error of
the mean. *p < 0.05 and **p < 0.01 vs. pre inhalation SABA,
short-acting b2 agonist; SAMA, short-acting muscarinic antag-
onist; IC at rest, inspiratory capacity at resting respiratory
rate; IC20, IC30, and IC40, inspiratory capacity at the rate of 20,
30 and 40 breaths per minute, respectively.before inhalation of SABA or SAMA. IC20, IC30 and IC40
significantly increased, and ICrest-30 and ICrest-40 significantly
decreased in the SABA group (Figs. 1 and 2). IC40 signifi-
cantly increased, and ICrest-40 significantly decreased in the
SAMA group. These findings suggest that the additive effi-
cacy of SABA on dynamic hyperinflation was superior to that
of SAMA.
Incremental shuttle walking test
Walking distance of the ISWT was significantly increased
following inhalation of SABA, but not following inhalation of
SAMA (Table 3). Maximum Borg scale for breathlessness
after walking (BSmax) was significantly increased following
inhalation of SAMA, suggesting that inhalation of SAMA did
not result in relief of breathlessness during exercise. In
contrast, BSmax remained unchanged following inhalationFigure 2 Effects of SABA or SAMA on dynamic hyperinflation
following metronome-paced incremental hyperventilation.
Decreases in inspiratory capacity from resting respiratory rates
to the rate of 20, 30, and 40 breath per minute before and
after inhalation of SABA or SAMA are shown. Values are
means  standard error of the mean. *p < 0.05 and **p < 0.01
vs. pre inhalation SABA, short-acting b2 agonist; SAMA, short-
acting muscarinic antagonist; ICrest-20, ICrest-30 and ICrest-40,
decreases in IC from ICat rest to IC20 (IC20eICat rest), from ICat rest
to IC30 (IC30eICat rest) and from ICat rest to IC40 (IC40eICat rest),
respectively.
Table 3 Effects of SABA or SAMA on the incremental shuttle walking test.
SABA (n Z 16) SAMA (n Z 16)
Pre Post Pre Post
Walking distance, m 281.9  21.1 301.3  21.3* 347.8  26.0 345.4  25.7
Lowest SpO2, % 88.7  1.4 88.1  1.3 85.9  1.5 85.6  1.3
PRmax, beats/minute 103.0  4.0 110.1  3.3 103.8  5.6 109.3  4.5
BSmax 4.9  0.6 5.1  0.6 5.8  0.3 6.1  0.3*
Values are means  standard error of the mean. *p < 0.05 and **p < 0.01 vs. pre inhalation.
SABA, short-acting b2 agonist; SAMA, short-acting muscarinic antagonist; PRmax, maximum pulse rate; BSmax, maximum Borg scale.
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relief of breathlessness during exercise. There were no
significant changes in maximum pulse rate and lowest SpO2
during exercise after the drug inhalation in either of the
groups. There was a significant correlation between the
increases in walking distance of the ISWT and the increases
in IC40 following inhalation of SABA (rZ 0.51, p < 0.05). In
contrast, there was no significant correlation between the
increases in walking distance of the ISWT and the increases
in FEV1 following inhalation of SABA.Discussion
Inhalation of SABA and SAMA improved airflow limitation and
dynamic hyperinflation in stable COPD patients who had
been treated with LAMA. Inhalation of SABA decreased
respiratory resistance and the difference in respiratory
resistance at 5 Hz and 20 Hz. Furthermore, inhalation of
SABA resulted in relief of breathlessness during exercise and
significant improvement in exercise capacity. On the whole,
the additive efficacy of SABA on airflow limitation, dynamic
hyperinflation and exercise tolerance was superior to that of
SAMA. The increases in IC40, but not the increases in FEV1,
had a significant correlation with the improvement in exer-
cise capacity following inhalation of SABA, thus suggesting
that significant improvement in exercise capacity may be
due to improvement in dynamic hyperinflation.
We previously demonstrated that both SABA and SAMA
are effective for reducing dynamic hyperinflation following
MPIH, and that SABA is more effective than SAMA in COPD
patients.6 Previous studies have demonstrated that SABA is
more effective for resting pulmonary function parameters
than SAMA in stable COPD patients with a regular treatment
with LAMA.15,16 In this study, the additive efficacy of SABA
on airflow limitation, dynamic hyperinflation and exercise
tolerance was superior to that of SAMA in stable COPD
patients treated with LAMA. These findings suggest that
SABA is better to use for relief of dyspnea as-needed in
stable COPD patients regardless of regular treatment with
LAMA.
Sukisaki et al. demonstrated that inhalation of proca-
terol hydrochloride (SABA) enhances the effect of exercise
training in the absence of any change in FEV1 during reha-
bilitation of COPD patients, and the effect lasted for at
least 4 h after inhalation.17 They also demonstrated that
the mean walking distance of the ISWT was significantly
increased by 37 m following inhalation of SABA in 19patients with moderate-to-severe COPD. In this study, it
was significantly increased by 19.4 m following inhalation of
SABA, which was smaller than the increase they demon-
strated, and did not reach a statistically significant increase
in the ISWT (>40 m)18 and the minimum clinically important
improvement for the ISWT (>47.5 m).19 The reason for the
difference between the studies may be because we inves-
tigated the additive efficacy of SABA in stable COPD
patients who had been treated with LAMA, and because
very severe COPD patients were included in this study.
BSmax of the ISWT remained unchanged following inha-
lation of SABA, probably due to the fact that it was ob-
tained at peak load during exercise, and walking distance
also significantly increased. If Borg scale score would be
obtained at the same load or at the same time during
exercise, it is thus speculated that Borg scale score would
decrease following inhalation of SABA.
Patients with COPD frequently report dyspnea related to
everyday tasks.20,21 They often decrease their physical
activity because exercise can worsen dyspnea. As a conse-
quence, they tend to have problems including exercise
deconditioning, relative social isolation, alteredmood states,
especially depression, muscle wasting, weight loss and oste-
oporosis.5,22 The progressive deconditioning associated with
inactivity initiates a vicious cycle, with dyspnea becoming
problematic at ever lower physical demands.5 To address
these problems, it is important to improve dyspnea in daily
life leading to decreased physical activity. Therefore, it is
noteworthy to pay attention to the additive efficacy of SABA
for stable COPD patients together with pulmonary rehabili-
tation. Single use of SABA before exercise, in addition to
regular treatment with LAMA, may therefore be useful in
stable COPD patients.
COPD increases the risk of cardiovascular disease by
two- to threefold20e23 by itself. Furthermore, stimulation
of b2-adrenergic receptors can produce resting sinus
tachycardia and has the potential to precipitate cardiac
rhythm disturbances in very susceptible patients, although
this appears to be a remarkably rare event with inhaled
therapy.5 Hypokalemia occurs with b2-adrenergic stimula-
tion as a result of intracellular shifts of potassium into
skeletal muscle,24 and has been associated with an
increased risk for ventricular tachycardia and fibrillation in
susceptible patients.25 Elevated heart rate has been shown
to be a strong independent risk factor for the development
of cardiomyopathy, coronary artery disease, fatal myocar-
dial infarction, sudden death, cardiovascular mortality, and
total mortality.26 In this study, there were no significant
Additive efficacy of short-acting bronchodilators in COPD 399changes in maximum pulse rate and lowest SpO2 during
exercise following the drug inhalation in either group.
However, it should be noted that SABA occasionally has
some adverse effects, particularly in patients with under-
lying ischemia, myocardial infarction, arrhythmia, or
congestive heart failure.
The possible effects of tachyphylaxis of short-acting
bronchodilators can be problematic in clinical practice.
However, previous studies have demonstrated the effec-
tiveness of long-term regular bronchodilator therapy with
procaterol hydrochroride27 and oxirtopium bromide28 in
stable COPD patients.
One limitation of this study is that the severity of COPD,
assessed according to the GOLD guidelines, tended to be
higher in the SAMA group and this may have influenced the
results. However, there were no significant differences in
severity of COPD and the results at baseline between the
groups. Another limitation of the study was the relatively
small sample size, and further larger studies are required to
confirm these results.
In conclusion, inhalation of SABA and SAMA improved
airflow limitation and dynamic hyperinflation in patients
with moderate-to-very severe COPD who had been treated
with LAMA. The additive efficacy of SABA was superior to
that of SAMA. Furthermore, inhalation of SABA resulted in
significant improvement in exercise capacity, which may
have been due to improvement in dynamic hyperinflation.
Single use of SABA before exercise, in addition to regular
treatment with LAMA, may therefore be useful in stable
COPD patients.
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